槲寄生化学成分的研究——Ⅳ.槲寄生新甙Ⅳ的结构

A new flavonoid, named viscumneoside Ⅳ, has been isolated from the ethanol extract of Viscum coloratura (Kom.) Nakai (Hu-Ji-Sheng, a Chinese folk medicine). On the basis of chemical transformations and spectral characteristics the structure of Ⅳ has been established as rhamnazin-3-0-β-D-(6″-β-hydroxy-β-methylglutaryl) glucoside.     

应用新型缝合器经腹腔镜行溃疡穿孔修补术

1995年3月。我们应用一种新型缝合器为6例消化性溃疡穿孔病人进行了囊腔镜穿孔修补术，初步经验表明，这是一种适用、易掌握和操作的器械。可显著地缩短手术时间。     

Subtalar joint coalition in children: new observations

Eleven children with clinical and radiographic findings suggestive of nonosseous subtalar coalition were found to have fibrous bridges at the time of surgery. A second group of 14 children with similar clinical and radiographic findings is being conservatively treated at present. This series of children suggests that a common site of nonosseous subtalar coalition is found posterior to the sustentaculum tali. Diagnosis of nonosseous coalition requires careful examination with computed tomography, with attention to subtle changes in the hindfoot, particularly posterior to the sustentaculum tali.     

槲寄生化学成分的研究——Ⅷ.2,3-丁二醇单葡萄糖甙的分离和结构

前文曾报道从中药槲寄生Viscum coloratum(Kom.)Nakai中分得黄酮、三萜和有机酸等化合物。现又从槲寄生的乙醇提取物中,经大孔吸附树脂层析和反复硅胶柱层析分得化合物Ⅷ～Ⅺ,经波谱分析和水解试验,确定Ⅷ的结构为2,3-丁二醇单葡萄糖甙;Ⅸ的结构为紫丁香甙;Ⅹ的结构为五加甙E;Ⅺ的结构为紫丁香甙元-O-β-D-芹糖基(1→2)葡萄糖甙。Ⅷ为一新结构的醇甙。     

腹腔镜胆囊切除术733例

1 临床资料腹腔镜胆囊切除术(LC)733(男441,女292)例,年龄21 ～78岁. 胆囊息肉105例,胆囊结石614例,结石并息肉14例,其中慢性萎缩性胆囊炎51例,胆囊管或颈部结石嵌顿伴胆囊急性炎症78例,胆囊坏疽1例.     

Microalbuminuria in hypertensive patients: evaluation of one-year treatment with irbesartan

BACKGROUND: Microalbuminuria is an important cardiovascular risk factor, and appears to be a marker of early arterial disease in patients with and without diabetes and/or hypertension. The aim of this study was to investigate prevalence of albuminuria in hypertensive patients in clinical settings, as well as to assess the efficacy of the angiotensin receptor blocker irbesartan on the evolution of this risk marker in habitual clinical practice. METHODS: KORAL-HT is a prospective, multicenter 1-year follow-up study in inadequately controlled hypertensive patients. Demographic data, major cardiovascular risk factors, albuminuria, and clinical parameters were recorded at baseline and at 6-month and 12-month visits. During the year of follow-up, the patients received antihypertensive therapy with irbesartan in addition to their usual antihypertensive regimen. RESULTS: A total of 1657 [802 diabetics (48.4%) and 855 nondiabetics (51.6%)] hypertensive patients were studied. The prevalence of microalbuminuria in this sample was 62.5%. After 1-year treatment with irbesartan, the percentage of patients with normoalbuminuria grew from 17.1% at baseline to 40.9% at 1-year follow-up. Blood pressure (BP) decreased from 157.3 +/- 13.7/93.6 +/- 9.2 mm Hg at baseline to 139.8 +/- 13.12 mm Hg and 136.1 +/- 11.6/80.1 +/- 8 mmHg at 6- and 12-month visits, respectively. The percentage of patients who achieved BP targets increased progressively, 57.2% at 6 months, and 70.1% at the study end. CONCLUSION: This study shows that the population attending Spanish HT centers have high prevalence of microalbuminuria. The addition of irbesartan to the usual treatment in poorly controlled hypertensive patients significantly improved BP control, and reduced microalbuminuria both in diabetic and nondiabetic patients. Our study confirms that similar results can be obtained in normal clinical practice as in controlled clinical trials.     

槲寄生化学成分的研究——Ⅲ.槲寄生新甙Ⅲ,Ⅴ,Ⅵ的结构

自槲寄生(Viscum coloratum(Kom.) Nakai)中分离得到五个黄酮甙。经光谱和化学分析确定Ⅰ为异鼠李素-3-O-β-D-葡萄糖甙,Ⅱ为异鼠李素-7-O-β-D-葡萄糖甙,Ⅲ为高圣草素-7-O-β-D-芹菜糖基(1→2)-β-D-葡萄糖甙;Ⅴ为高圣草素-7-O-β-D-芹菜糖(1→5)-β-D-芹菜糖(1→2)-β-D-葡萄糖甙;Ⅵ为高圣草素-7-O-β-D-(6″-乙酰)-葡萄糖甙。化合物Ⅲ,Ⅴ,Ⅵ为三个新的双氢黄酮甙,分别命名为槲寄生新甙Ⅲ(viscumneoside Ⅲ),槲寄生新甙Ⅴ(viscumneoside Ⅴ)和槲寄生新甙Ⅵ(viscumneoside Ⅵ)。Ⅰ和Ⅱ亦系首次从该植物中发现。